Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

By Michael Erman SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with ...

Pfizer is acquiring Metsera, a clinical-stage biopharmaceutical company with a focus on medicines for obesity and cardiometabolic diseases, in a deal valued at up to $7.3 billion. “Pfizer said it ...

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

(Reuters) - Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is ...

Pfizer's (NYSE:PFE) entry into the obesity treatment market through its $4.9B deal to acquire Metsera (NASDAQ:MTSR) is the latest indication that Big Pharma wants a piece of the weight loss drugs pie ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved ...

President Trump, during an Oval Office event Tuesday, called out Albert Bourla, the CEO of Pfizer, for overcharging Americans for prescription drugs. "The United States has just 4% of the world’s ...

The Trump administration and Pfizer PFE announced an agreement on Sept. 30 that includes most-favored-nation pricing for Pfizer’s drugs in Medicaid programs, discounts for direct sales of Pfizer drugs ...